Group items tagged

The UK recorded an estimated 66,730 serious antibiotic-resistant infections in 2023, surpassing the pre-pandemic figure of 62,314 in 2019, a new report from the UK Health Security Agency (UKHSA) has revealed. Antibiotic resistant bacteria are less likely to respond to treatment and can cause serious complications, including bloodstream infections, sepsis and hospitalisation. The national surveillance data published by the UKHSA showed that E. coli - a common cause of urinary tract infections, diarrhoea, vomiting and fever, accounted for 65 per cent of antibiotic-resistant bloodstream infections in the last five years. The English Surveillance of Antibiotic Prescribing and Utilisation Report (ESPAUR) highlighted a stark disparity in infection rates. People in the most deprived communities were 42.6 per cent more likely to experience an antibiotic-resistant infection in 2023 compared to those in the least deprived areas, a significant rise from 29.4 per cent in 2019. Overall, resistant infection rates in the most deprived areas of England increased by 9.5 per cent between 2019 and 2023.

Here in this special issue of 'Emerging Healthcare Solution Providers to Watch in 2019', we have enlightened the foremost Healthcare Solution Providers that are transforming the healthcare industry with their astounding services and approaches.

Immuno-Transcriptomics firm Novigenix has received positive results from its early colon cancer detection blood test at the European Society for Medical Oncology (ESMO) 2019.

The British Generic Manufacturers Association (BGMA) has published a positioning paper which sets out the objectives that need to be delivered through the next Voluntary Pricing and Access Scheme (VPAS) on Thursday (15 June). The paper details how a financially sustainable VPAS can support widened medicines access to patients. VPAS is an agreement between the Department of Health and Social Care (DHSC), NHS England and The Association of the British Pharmaceutical Industry (ABPI). The scheme aims to limit increases in spending on branded medicines to no more than 2% per year via a rebate system which is charged on companies' sales revenues. Two years ago, the rate was 5.1% but for 2023 it has soared to 26.5%. Last year, the association had raised concerns over the rise in the VPAS rate for 2023 to 26.5 per cent. "The rocketing rate is in large part due to the growth in spend in on-patent medicines since 2019. Looking at the four completed years of the current VPAS scheme, data shows that the average annual growth rate for on-patent medicine sales value from 2019-22 was 18% compared to just 2% for off-patent products," said the association.

The Company Chemists Association (CCA)'s workforce finding showed that by 2024 eight years' worth of growth of the pharmacist workforce will have been funnelled away from community pharmacies. "In 2019, when NHS leaders realised they were unable to find enough GPs to meet the public's needs, they hastily decided to recruit pharmacists and other healthcare professionals to fill the gaps. This was implemented without any corresponding efforts to increase the supply of pharmacists, creating huge shortages," said CCA. "The bulk of the NHS's recruitment drive was paid for using additional money ringfenced by the NHS - the £2.4bn Additional Roles Reimbursement Scheme (ARRS). We estimate over the life course of ARRS funding (2019-2024), the equivalent of eight years of growth in the number of pharmacists in England will have been funnelled directly into primary care at the expense of other sectors. At the current rate, CCA estimate that community pharmacy will have experienced the equivalent of three fallow years by 2024. To ensure the pharmacy network is protected and able to take pressure off other parts of the NHS, there are several urgent measures which must be implemented. Countering the impact of primary care recruitment: Community pharmacists should be commissioned to provide 'packages of care' on behalf of GPs, rather than taking pharmacists away from accessible high street settings.

Long waits for an ambulance or surgery led to the death of 112 people, and nearly 8,000 more people suffered harm while waiting for help in England last year. The data from NHS England, obtained by The Guardian, show that patient deaths arising directly from care delays have risen more than fivefold over the last three years. In 2019, there were 21 patient deaths due to NHS care delays, and 96 people suffered "severe harm" as compared to 152 last year. Adult mental health care was mostly affected with 471 patients experiencing harm due to delays, followed by childbirth care (253), eye problems (221), and trauma and general surgery (207). There has been increase of 97 percent in the overall number of people suffering some degree of harm, from 3,979 in 2019 to 7,856 in 2022.

The British Generic Manufacturers Association (BGMA) has raised concerns over the rise in the VPAS rate for 2023 to 26.5 per cent. The Department of Health Social Care (DHSC) today announced that the 2019 voluntary scheme payment percentage for 2023 will be 26.5%. The 2019 voluntary scheme for branded medicines pricing and access is an agreement between the Department of Health and Social Care, NHS England and the Association of the British Pharmaceutical Industry. BGMA believes that the high VPAS tax for 2023 risks more medicines shortages, rising prices for the NHS via reduced competition, and new medicine launches to the UK being deferred. Mark Samuels, Chief Executive of BGMA, said: "Raising the VPAS tax to 26.5% will damage the UK's medicines supply because it will make some products lossmaking. It is more than a five-fold tax increase from 2021, and no industry can cope with this unpredictable and exceptional tax volatility.

The Department of Health and Social Care (DHSC) in recent response to the questions asked by members of the House of Lords addressed the concerning trend of pharmacy closures in rural areas across the UK. Led by The Bishop of St Albans, inquiries focused on the number of community pharmacies that had ceased operations over the past five years and the ongoing financial challenges faced by those remaining in rural regions. Lord Markham, the Parliamentary Under-Secretary for Health and Social Care, provided insights into the stark reality confronting rural communities. Highlighting data as per Guide to applying the Rural Urban Classification to data (2019-2023) Markham illustrated the significant closure rates of rural pharmacies compared to the limited number of new openings between 2019 and 2023. The figures revealed a fluctuating trend over the past five years, indicating a dynamic landscape within rural pharmacy provision.

"Record long NHS waits are forcing huge numbers of people out of work, including doctors and nurses," said Wes Streeting MP, Labour's Shadow Health and Social Care Secretary as Labour announced a new partnership with Nuffield Health today to tackle joint pain issues among NHS staff and reducing waiting lists. Musculoskeletal problems, including back, knee, hip, and neck pain, are the second leading cause of NHS staff absences, surpassed only by mental health issues. In December 2023 alone, NHS workers missed a record 198,000 days due to these issues, marking a 13 per cent increase from the 174,000 days recorded in December 2019. Nurses and health visitors accounted for 52,000 of these days, up from 47,000 pre-pandemic, while doctors took 3,500 days off, a 9 per cent increase from 2019. The partnership with Nuffield Health will provide up to 4,000 extra places for NHS staff in Nuffield Health's Joint Pain Programme at no cost.

RPS Wales will once again spearhead the development of new three-year goals to help pharmacy in Wales advance toward its 2030 vision as outlined in Pharmacy: Delivering a Healthier Wales (PDaHW). Elen Jones, Director of RPS Wales, and Jonathan Simms, Chair of the Welsh Pharmaceutical Committee, announced during the recent RPS Wales Conference. Jones said: "I'd like to thank the Welsh Government and the Welsh Pharmaceutical Committee for once again entrusting RPS to take this work forward." This iteration of PDaHW builds on the original 10-year plan, published in 2019, and the two series of stepping stone goals established from 2019-2022 and 2022-2025. Work on the new three-year goals will begin in early 2025.

A new report published by the NHS Business Services Authority (NHSBSA) reveals that 24,300 dentists performed NHS dental activity in England in 2023/24, marking a 0.4 per cent rise from the previous year's 24,227. However, this figure represents a 1.5 per cent decrease from 24,700 dentists with NHS activity in 2019/20. The report covers NHS dental activity and the NHS dental workforce in England from 2019/20 to 2023/24. It is the first release from NHSBSA following the transition from NHS England, which previously issued the report. There were 34 million courses of dental treatment in England for 2023/24, a 4.3 per cent increase from 2022/23. The total units of dental activity (UDAs) rose by 3.4 per cent to 73 million.

Public health experts are calling for a stronger, comprehensive government intervention to tackle the escalating levels of alcohol-related harm in England, as new data reveals a significant rise in alcohol deaths. Official figures indicate a "catastrophic rise" in alcohol-related deaths, with 8,274 people dying in 2023 alone-a 42% increase since 2019. Official figures indicate a "catastrophic rise" in deaths caused solely by alcohol, with 8,274 people dying in 2023 alone-a 42 per cent increase since 2019. The North East recorded the highest mortality rates, more than double those in London. The Alcohol Health Alliance (AHA), which represents 60 organisations working to reduce alcohol-related harm, has warned that this number represents only the tip of the iceberg as it reflects deaths wholly attributable to alcohol. When cases where alcohol was a contributing factor are considered, the death toll could triple the current estimates, they said.

From CBD infused-foods to dairy-free alternatives, Verdict Foodservice rounds up some of the health food trends that are launching across restaurants in 2019.

The NHS England is rapidly expanding the targeted lung health check programme (TLHC) across England to detect lung cancers at an early stage. Launched in 2019, it is a national scheme that identifies people aged 55-74 at increased risk of lung cancer to invite them for a lung health check and chest CT scan, if appropriate. Since then, it has heled detect over 3,000 lung cancers, mostly at an early stage when the condition is more treatable, Dr Jason Page, Clinical Director of South Yorkshire and Bassetlaw targeted lung health checks, revealed in a blog on the NHS website. The decision to initiate the programme follows a study that showed CT screening reduced lung cancer mortality by 26 per cent in men and between 39 per cent and 61 per cent in women.

The total European market for cosmetic surgery, facial aesthetics and medical lasers will approach €1.18 billion by 2019.This market includes botulinum toxin A, dermal fillers, breast implants, non-breast implants, aesthetic laser and light therapy devices, non-invasive skin tightening devices and non-invasive fat reduction devices.

Digital health interventions (DHIs) are fast emerging as vital tools to promote personal health and provide essential services. DHIs can be accessed through mobile phones, tablets and computers, as well as serve as effective support systems to improve personal health.

Research and development (R&D) in liquid biopsy is increasingly being funded by both public and private sectors due to its promising features such as early detection of cancer tumour, new lesion characterisation and identification of cancer drug target.

Community pharmacy may have to share workload as NHS emergency service - 999 - has faced the busiest ever month in October with staff attending to a record 1,012,143 calls, data released today (November 11) has revealed. Of the total, 82,000 were life threatening call-outs, an increase from 61,561 in October 2019. Besides, major A&Es treated over 1.4 million people during October and the NHS Covid Vaccination Programme delivered more than 7.5 million jabs, including more than 5.9 million top-up jabs. Professor Stephen Powis, NHS national medical director, said the latest data show that "pressure on the health service remains incredibly high," therefore, people with minor illness should "contact their local pharmacists." He encouraged people to come forward to take Covid and flu jabs.

Community pharmacies in England will have to go through a clinical audit focusing on valproate, following an agreement reached between the PSNC and NHS England and NHS Improvement (NHSE&I). The audit, a part of NHS contractual requirements, aims to reduce the potential harm caused by taking valproate during pregnancy. The 2021/22 audit will be based on the Pharmacy Quality Scheme (PQS) audit, allowing contractors to close the cycle by re-auditing their practice. NHSE&I recently shared the results of the PQS 2019/20 valproate audit. Around 5.6 per cent of the 12,068 girls or women of childbearing potential who participated in the audit said they were not advised in line with the MHRA Drug Safety Update 2018 relating to the potential impact on an unborn child.